TY - JOUR PY - 2017 DA - 2017// TI - Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 JO - Lancet Respir Med VL - 5 UR - https://doi.org/10.1016/S2213-2600(17)30293-X DO - 10.1016/S2213-2600(17)30293-X ID - ref1 ER - TY - JOUR PY - 2016 DA - 2016// TI - Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 JO - Lancet VL - 388 UR - https://doi.org/10.1016/S0140-6736(16)31678-6 DO - 10.1016/S0140-6736(16)31678-6 ID - ref2 ER - TY - BOOK PY - 2019 DA - 2019// TI - Global Strategy for the Diagnosis, Management and Prevention of COPD ID - ref3 ER - TY - BOOK PY - 2018 DA - 2018// TI - 2018 GINA Report, Global Strategy For Asthma Management and Prevention ID - ref4 ER - TY - JOUR AU - Aparici, M. AU - Carcasona, C. AU - Ramos, I. PY - 2017 DA - 2017// TI - Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist /β2-adrenoceptor agonist (MABA) molecule JO - Pulm Pharmacol Ther VL - 46 UR - https://doi.org/10.1016/j.pupt.2017.07.003 DO - 10.1016/j.pupt.2017.07.003 ID - Aparici2017 ER - TY - JOUR AU - Aparici, M. AU - Carcasona, C. AU - Ramos, I. PY - 2019 DA - 2019// TI - Pharmacological profile of AZD8871 (LAS191351), a novel inhaled dual M3 receptor antagonist/ β2-adrenoceptor agonist molecule with long-lasting effects and favorable safety profile JO - J Pharmacol Exp Ther VL - 370 UR - https://doi.org/10.1124/jpet.118.255620 DO - 10.1124/jpet.118.255620 ID - Aparici2019 ER - TY - JOUR AU - Hughes, A. D. AU - Jones, L. H. PY - 2011 DA - 2011// TI - Dual-pharmacology muscarinic antagonist and β2 agonist molecules for the treatment of chronic obstructive pulmonary disease JO - Future Med Chem VL - 3 UR - https://doi.org/10.4155/fmc.11.106 DO - 10.4155/fmc.11.106 ID - Hughes2011 ER - TY - JOUR AU - Singh, D. AU - Astbury, C. AU - Jimenez, L. PY - 2017 DA - 2017// TI - A randomized placebo and active controlled trial of AZD8871 a novel dual acting bronchodilator in COPD patients JO - Eur Respir J VL - 50 ID - Singh2017 ER - TY - JOUR AU - Ramamoorthy, A. AU - Pacanowski, M. A. AU - Bull, J. AU - Zhang, L. PY - 2015 DA - 2015// TI - Racial/ethnic differences in drug disposition and response: review of recently approved drugs JO - Clin Pharmacol Ther VL - 97 UR - https://doi.org/10.1002/cpt.61 DO - 10.1002/cpt.61 ID - Ramamoorthy2015 ER - TY - JOUR AU - Salpeter, S. R. AU - Ormiston, T. M. AU - Salpeter, E. E. PY - 2004 DA - 2004// TI - Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis JO - Chest. VL - 125 UR - https://doi.org/10.1378/chest.125.6.2309 DO - 10.1378/chest.125.6.2309 ID - Salpeter2004 ER - TY - JOUR AU - Singh, D. AU - Fuhr, R. AU - Jimenez, L. PY - 2019 DA - 2019// TI - A randomized trial of dual-acting bronchodilator AZD8871 for chronic obstructive pulmonary disease JO - Am J Respir Crit Care Med VL - 199 UR - https://doi.org/10.1164/rccm.201812-2345LE DO - 10.1164/rccm.201812-2345LE ID - Singh2019 ER - TY - JOUR AU - Battisti, W. P. AU - Wager, E. AU - Baltzer, L. PY - 2015 DA - 2015// TI - Good publication practice for communicating company-sponsored medical research: GPP3 JO - Ann Intern Med VL - 163 UR - https://doi.org/10.7326/M15-0288 DO - 10.7326/M15-0288 ID - Battisti2015 ER -